The first-of-its-kind AI-driven, non-blood-contact smart closed-loop diagnostic and treatment platform for heart conditions

Product Development and Scientific Validation: Active Soft Robotic Heart Support Device

From Concept to Evidence: A Solid Foundation of Preclinical Research

Our confidence in the ASD platform is grounded in extensive experimental data. Across multiple animal models, the ASD system has demonstrated multifunctional therapeutic benefits:

1. Mechanical Support Effectiveness: In rodent models, ASD demonstrated the ability to improve cardiac output and reverse adverse ventricular remodeling。

2. Advantages in Targeted Drug Delivery: Epicardial drug delivery via the ASD showed significantly higher bioavailability and therapeutic efficacy compared with intravenous administration (e.g., lidocaine for anti-arrhythmia, Danshen injection for heart failure therapy).

3. A Carrier for Innovative Therapies: We have successfully delivered novel therapeutic agents — such as photosynthetic microorganisms and stem cells — through the ASD, opening new avenues for future treatment paradigms.

These findings have been published in multiple peer-reviewed journals, providing a strong scientific foundation for advancing ASD technology from the laboratory towards clinical application.

Active Soft Robotic Cardiac Support Device (ASD): Product Development Roadmap

We have formulated a clear strategic path to bring the ASD platform to clinical and market applications:

Phase I: Preclinical Development & System Optimisation (2026 – 2027)

• Milestones: Completion of large-animal studies; identification of GMP manufacturing partners; integration of core sensing and algorithm modules.

• Use of Funds: Team expansion, prototype iteration, regulatory consultation.

Phase II: First-in-Human Study (2027–2028)

• Milestones: Initiation and completion of the first human feasibility study, validating safety and preliminary efficacy.

Phase III: Pivotal Clinical Trials & Market Preparation (2029–2031+)

• Milestones: Launch of pivotal clinical trials, submission of regulatory applications, and commercial launch preparation.

Partnerships & Investment: We are seeking mission-aligned partners to advance this transformative cardiac recovery technology together.

• Investors: Join us in supporting a platform technology with a strong IP portfolio, a clear development pathway, and significant global market potential.

• Strategic Collaborators: Partner with us in areas such as sensing technology, AI algorithms, novel biologics, or clinical development.

• Top Talents: Join our passionate, interdisciplinary team to tackle the most challenging clinical problems in heart failure.